Type II Interleukin-4 Receptor Activation in Basal Breast Cancer Cells Promotes Tumor Progression via Metabolic and Epigenetic Modulation
Open Access
- 24 April 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4647
Abstract
Interleukin-4 (IL4) is a Th2 cytokine that can signal through two different receptors, one of which—the type II receptor—is overexpressed by various cancer cells. Previously, we have shown that type II IL4 receptor signaling increases proliferation and metastasis in mouse models of breast cancer, as well as increasing glucose and glutamine metabolism. Here, we expand on those findings to determine mechanistically how IL4 signaling links glucose metabolism and histone acetylation to drive proliferation in the context of triple-negative breast cancer (TNBC). We used a combination of cellular, biochemical, and genomics approaches to interrogate TNBC cell lines, which represent a cancer type where high expression of the type II IL4 receptor is linked to reduced survival. Our results indicate that type II IL4 receptor activation leads to increased glucose uptake, Akt and ACLY activation, and histone acetylation in TNBC cell lines. Inhibition of glucose uptake through the deletion of Glut1 ablates IL4-induced proliferation. Additionally, pharmacological inhibition of histone acetyltransferase P300 attenuates IL4-mediated gene expression and proliferation in vitro. Our work elucidates a role for type II IL4 receptor signaling in promoting TNBC progression, and highlights type II IL4 signaling, as well as histone acetylation, as possible targets for therapy.Keywords
Funding Information
- Office of the Secretary of Defense (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- National Cancer Institute (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- NRSA F31 Award (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- National Cancer Institute (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- National Institutes of Health (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- National Institutes of Health (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- National Eye Institute (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
- National Institutes of Health (W81XWH-16-1-0559, T32CA119925, CA247131, P30 CA68485, 1S10OD018015, 5UL1 RR024975-03, P30 EY08126, G20 RR030956)
This publication has 67 references indexed in Scilit:
- The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophagesCell Reports, 2023
- BCL-2 protein family: attractive targets for cancer therapyApoptosis, 2022
- Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone AcetylationJournal of Bone and Mineral Research, 2020
- ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTORClinical and Translational Oncology, 2020
- Glycolytic Stimulation Is Not a Requirement for M2 Macrophage DifferentiationCell Metabolism, 2018
- Interleukin‐4 induces a CD44high/CD49bhigh PC3 subpopulation with tumor‐initiating characteristicsJournal of Cellular Biochemistry, 2018
- Histone H3k9 and H3k27 Acetylation Regulates IL‐4/STAT6‐Mediated Igε Transcription in B LymphocytesThe Anatomical Record, 2015
- IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growthBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2015
- Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule InhibitorChemistry & Biology, 2010
- IL-4-DEPENDENT INDUCTION OF BCL-2 AND BCL-XLIN ACTIVATED T LYMPHOCYTES THROUGH A STAT6- AND PI 3-KINASE-INDEPENDENT PATHWAYCytokine, 2000